The dual offering signals aggressive funding needs ahead of potential commercialization, despite no revenue. The $750M equity raise will dilute existing shareholders meaningfully. Combined with recent insider selling, this raises concerns about valuation and capital efficiency. Watch for final pricing and conversion terms of the notes, which will impact long-term dilution.
Price Chart
Executive Summary
Revolution Medicines announced two concurrent capital raises: a $750 million common stock offering and a $250 million convertible note offering due 2033, with over-allotment options totaling $150 million. The offerings are not contingent on each other, and proceeds will fund R&D and potential commercialization of its RAS-targeted oncology pipeline.
Key Financial Metrics
Key Facts
- Company is conducting a $750 million common stock offering and a $250 million convertible senior notes offering due 2033.
- Underwriters have 30-day options to purchase up to an additional $112.5 million in stock and $37.5 million in notes.
- Offerings are not contingent on each other.
- Net proceeds will be used for R&D, commercialization planning, general corporate purposes, and capital expenditures.
- Recent insider selling: 8 transactions totaling $3.1M in the past 30 days.
Financial Impact
Total $1 billion in capital raised through equity and convertible debt, with significant near-term dilution from the stock offering.
Risk Factors
- Significant shareholder dilution from the $750M common stock offering.
- Convertible notes introduce future equity risk if converted, especially if stock price exceeds conversion threshold.
- No revenue or profitability timeline disclosed; continued heavy R&D spend increases execution risk.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3272883 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 15, 2026 16d ago | 144 | $195.92 $190.74 | ▼ −2.64% | ▼ −5.21% | $206.54 (+5.42%) |
Sep 15, 2026 16d ago | 144 | $195.92 $190.74 | ▼ −2.64% | ▼ −5.21% | $206.54 (+5.42%) |
Sep 15, 2026 17d ago | Insider Cluster | $204.86 $190.95 | ▼ −6.79% | ▼ −7.61% | $206.54 (+0.82%) |
Sep 14, 2026 17d ago | Insider Cluster | $204.86 $192.86 | ▼ −5.86% | ▼ −7.98% | $206.54 (+0.82%) |
Aug 26, 2026 5w ago | 8-K | $215.44 $209.23 | ▼ −2.88% | ▼ −2.76% | $206.54 (−4.13%) |
Aug 26, 2026 5w ago | Press Release | $215.44 $209.23 | ▼ −2.88% | ▼ −2.76% | $206.54 (−4.13%) |
Aug 25, 2026 5w ago | Insider Cluster | $211.38 $209.87 | ▼ −0.71% | ▼ −0.18% | $206.54 (−2.29%) |
Jul 2, 2026 13w ago | Press Release | $189.24 $191.13 | ▲ +1.00% | ▲ +0.07% | $206.54 (+9.14%) |
Jul 1, 2026 13w ago | Insider Cluster | $187.51 $190.46 | ▲ +1.57% | ▲ +1.31% | $206.54 (+10.15%) |
Jun 22, 2026 14w ago | 8-K | $165.81 $192.62 | ▲ +16.17% | ▲ +16.62% | $206.54 (+24.56%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access